Ionis Pharmaceuticals Inc. (IONS)
NASDAQ: IONSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:09 PM ET
IONS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.14B
- EPS (TTM)
- -$3.48
- Dividend yield
- None
- 52-week range
- 42.63 – 86.74
- Day range
- 42.95 – 44.19
- Volume / Avg
- 754.01K / 3.78M
- Beta
- —
- Shares outstanding
- 166.18M
- Next earnings
- Nov 4, 2026
52-week range
IONS stock today
Ionis Pharmaceuticals (IONS) is trading at $42.96 on Oct 8, down 2.73% (-$1.20), versus the S&P 500's 0.36% decline. Shares are 50.5% below their 52-week high of $86.74, set on Feb 5, 2026 and 0.8% above the 52-week low of $42.63, near the bottom of the past year's range. IONS is down 44.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 35.9%.
Ionis Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$3.48), so its P/E ratio is not meaningful. Ionis Pharmaceuticals's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Ionis Pharmaceuticals
Company profileIonis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Brett P. Monia Ph.D.
- Headquarters
- Carlsbad, CA
- Employees
- 1,480
- Website
- ionis.com
Financial highlights
Full financialsIn fiscal 2025, Ionis Pharmaceuticals generated $943.7 million in revenue, up 33.8% from fiscal 2024. Ionis Pharmaceuticals reported a net loss of $381.4 million, compared with a loss of $453.9 million a year earlier. Gross margin was 98.3% (down from 98.4%) and operating margin -40.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $943.71M | $705.14M | $787.65M | $587.37M | $810.46M |
| Growth | +33.83% | -10.48% | +34.10% | -27.53% | +11.13% |
| Net income | $-381.39M | $-453.90M | $-366.29M | $-269.72M | $-28.60M |
| EPS (diluted) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
Analyst forecast
ForecastConsensus (23 analysts)
buy
Avg. price target
$83.64+94.72%
- Strong buy 9
- Buy 9
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-1.20
- Last reported (Q2 2026)
- Jul 29, 2026
- EPS actual vs est.
- $-0.69 vs —
IONS news
All IONS news- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNasdaqNVS, IONS, ACIU, PGEN
- Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsNasdaqIONS, AZN, NVS
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNasdaqNVS, RGEN, ANIK, IONS
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG DealsNasdaqAPVO, ASND, AZN, BIIB
Ionis Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABVXAbivax SA ADR | 84.11 | -3.33% | $7.34B | vs IONS |
| PRAXPraxis Precision Medicines Inc. | 263.19 | -5.34% | $7.35B | vs IONS |
| SYRESpyre Therapeutics Inc. | 77.13 | -4.60% | $7.12B | vs IONS |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.05 | -3.05% | $6.64B | vs IONS |
| TGTXTG Therapeutics Inc. | 52.27 | -1.29% | $8.00B | vs IONS |
| ALKSAlkermes plc | 39.45 | -4.83% | $6.62B | vs IONS |
| CYTKCytokinetics Incorporated | 59.81 | -2.14% | $8.31B | vs IONS |
| ARWRArrowhead Pharmaceuticals Inc. | 59.44 | -3.33% | $8.40B | vs IONS |
Indexes, lists and sector
Ionis Pharmaceuticals stock FAQ
What is Ionis Pharmaceuticals's stock price today?
IONS last traded at $42.96 as of Oct 8, 12:09 PM EDT, down 2.73% on the day. Prices are delayed at least 15 minutes.
When is Ionis Pharmaceuticals's next earnings date?
Ionis Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-1.20.
Who is Ionis Pharmaceuticals's CEO?
Dr. Brett P. Monia Ph.D. is the chief executive officer of Ionis Pharmaceuticals Inc., which has about 1,480 employees.
What is the IONS 52-week high?
The 52-week high for IONS is $86.74 and the 52-week low is $42.63. The stock is currently 50.5% below its high.